Heart Repair Venture Undeterred By Risk; Is “Biopacing” Next For Medtronic?
This article was originally published in The Gray Sheet
Executive Summary
MG Biotherapeutics' initial focus on autologous cell repair of the heart, if successful, will give the joint venture a "commercial bridge" to further combination product development, Genzyme Exec VP Earl Collier said at Medtronic's annual investor conference Oct. 5